BioNTech Results Presentation Deck

Q2 2020 highlights 0000 5 $ es ))))) I I I 12 immunotherapies across 3 drug classes now in the clinic (mRNA, Antibodies, Small molecule) Initiated pivotal Phase 2b/3 trial for BNT162b2 COVID-19 vaccine Commercial supply agreements signed for >250 million doses of BNT162 in 2020/21, subject to approval or emergency authorization Published Phase 1 data and started recruiting for randomized Phase 2 trials of iNeST in adjuvant cancers First patient dosed in FIH Phase 1/2 trial of BNT411 small molecule TLR7 agonist Ongoing scale-up of mRNA manufacturing infrastructure and supply chain in Germany Strategic collaboration with Regeneron to conduct randomized Phase 2 trial with Libtayo® and Fix Vac in Melanoma Entered agreements for $1.1 billion in gross proceeds from non-dilutive payments and equity / debt financings in year to-date BIONTECH

View entire presentation